Gut Bacterial Community Determines the Therapeutic Effect of Ginsenoside on Canine Inflammatory Bowel Disease by Modulating the Colonic Mucosal Barrier
Abstract
:1. Introduction
2. Materials and Methods
2.1. Materials
2.2. Extraction and HPLC Analysis of Ginsenoside
2.3. Animal and Treatment Protocols
2.4. Canine Inflammatory Bowel Disease Activity Indices
2.5. Histopathological Analysis
2.6. Immunohistochemical Analysis
2.7. Microbiota Analysis
2.8. Statistical Analysis
3. Results
3.1. HPLC Analysis of Ginsenoside
3.2. Effect of DSS-Induced IBD in Dogs
3.3. Bacterial Community Analysis of Colonic Mucosa in Dogs with IBD
3.4. Ameliorative Effect of Ginsenoside on IBD in Dogs
3.5. Effect of Ginsenoside on Colonic Mucosal Bacterial Community in Dogs with IBD
3.6. Correlation Analysis between Key Bacteria and Physiological Indices
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Ng, S.C.; Shi, H.Y.; Hamidi, N.; Underwood, F.E.; Tang, W.; Benchimol, E.I.; Panaccione, R.; Ghosh, S.; Wu, J.C.Y.; Chan, F.K.L.; et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. Lancet 2017, 390, 2769–2778. [Google Scholar] [CrossRef] [PubMed]
- Kaplan, G.G. The global burden of IBD: From 2015 to 2025. Nat. Rev. Gastroenterol. Hepatol. 2015, 12, 720–727. [Google Scholar] [CrossRef] [PubMed]
- Dahlhamer, J.M.; Zammitti, E.P.; Ward, B.W.; Wheaton, A.G.; Croft, J.B. Prevalence of Inflammatory Bowel Disease among Adults Aged ≥18 Years—United States, 2015. MMWR Morb. Mortal Wkly. Rep. 2016, 65, 1166–1169. [Google Scholar] [CrossRef] [PubMed]
- Buckley, A.; Turner, J.R. Cell Biology of Tight Junction Barrier Regulation and Mucosal Disease. Cold Spring Harb. Perspect. Biol. 2018, 10, a029314. [Google Scholar] [CrossRef]
- Turner, J.R. Intestinal mucosal barrier function in health and disease. Nat. Rev. Immunol. 2009, 9, 799–809. [Google Scholar] [CrossRef]
- de Medina, F.S.; Romero-Calvo, I.; Mascaraque, C.; Martínez-Augustin, O. Intestinal inflammation and mucosal barrier function. Inflamm. Bowel Dis. 2014, 20, 2394–2404. [Google Scholar] [CrossRef]
- Capaldo, C.T.; Powell, D.N.; Kalman, D. Layered defense: How mucus and tight junctions seal the intestinal barrier. J. Mol. Med. 2017, 95, 927–934. [Google Scholar] [CrossRef]
- Ni, J.; Wu, G.D.; Albenberg, L.; Tomov, V.T. Gut microbiota and IBD: Causation or correlation? Nat. Rev. Gastroenterol. Hepatol. 2017, 14, 573–584. [Google Scholar] [CrossRef]
- Groschwitz, K.R.; Hogan, S.P. Intestinal barrier function: Molecular regulation and disease pathogenesis. J. Allergy Clin. Immunol. 2009, 124, 3–20. [Google Scholar] [CrossRef]
- Suzuki, T. Regulation of intestinal epithelial permeability by tight junctions. Cell. Mol. Life Sci. 2013, 70, 631–659. [Google Scholar] [CrossRef]
- Zihni, C.; Mills, C.; Matter, K.; Balda, M.S. Tight junctions: From simple barriers to multifunctional molecular gates. Nat. Rev. Mol. Cell Biol. 2016, 17, 564–580. [Google Scholar] [CrossRef]
- Zhao, Q.; Maynard, C.L. Mucus, commensals, and the immune system. Gut Microbes 2022, 14, 2041342. [Google Scholar] [CrossRef]
- Hansson, G.C.; Johansson, M.E. The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Gut Microbes 2010, 1, 51–54. [Google Scholar] [CrossRef]
- Johansson, M.E.; Phillipson, M.; Petersson, J.; Velcich, A.; Holm, L.; Hansson, G.C. The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proc. Natl. Acad. Sci. USA 2008, 105, 15064–15069. [Google Scholar] [CrossRef]
- Johansson, M.E.; Gustafsson, J.K.; Holmén-Larsson, J.; Jabbar, K.S.; Xia, L.; Xu, H.; Ghishan, F.K.; Carvalho, F.A.; Gewirtz, A.T.; Sjövall, H.; et al. Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis. Gut 2014, 63, 281–291. [Google Scholar] [CrossRef]
- Lian, Q.; Yan, S.; Yin, Q.; Yan, C.; Zheng, W.; Gu, W.; Zhao, X.; Fan, W.; Li, X.; Ma, L.; et al. TRIM34 attenuates colon inflammation and tumorigenesis by sustaining barrier integrity. Cell. Mol. Immunol. 2021, 18, 350–362. [Google Scholar] [CrossRef]
- Wlodarska, M.; Thaiss, C.A.; Nowarski, R.; Henao-Mejia, J.; Zhang, J.P.; Brown, E.M.; Frankel, G.; Levy, M.; Katz, M.N.; Philbrick, W.M.; et al. NLRP6 inflammasome orchestrates the colonic host-microbial interface by regulating goblet cell mucus secretion. Cell 2014, 156, 1045–1059. [Google Scholar] [CrossRef]
- van der Post, S.; Jabbar, K.S.; Birchenough, G.; Arike, L.; Akhtar, N.; Sjovall, H.; Johansson, M.E.V.; Hansson, G.C. Structural weakening of the colonic mucus barrier is an early event in ulcerative colitis pathogenesis. Gut 2019, 68, 2142–2151. [Google Scholar] [CrossRef]
- Martens, E.C.; Neumann, M.; Desai, M.S. Interactions of commensal and pathogenic microorganisms with the intestinal mucosal barrier. Nat. Rev. Microbiol. 2018, 16, 457–470. [Google Scholar] [CrossRef]
- Cai, Z.; Wang, S.; Li, J. Treatment of Inflammatory Bowel Disease: A Comprehensive Review. Front. Med. 2021, 8, 765474. [Google Scholar] [CrossRef]
- Colombel, J.F.; D’Haens, G.; Lee, W.J.; Petersson, J.; Panaccione, R. Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review. J. Crohns Colitis 2020, 14, 254–266. [Google Scholar] [CrossRef]
- Frøslie, K.F.; Jahnsen, J.; Moum, B.A.; Vatn, M.H. Mucosal healing in inflammatory bowel disease: Results from a Norwegian population-based cohort. Gastroenterology 2007, 133, 412–422. [Google Scholar] [CrossRef]
- Vatn, M.H. Mucosal healing: Impact on the natural course or therapeutic strategies. Dig. Dis. 2009, 27, 470–475. [Google Scholar] [CrossRef]
- Riaz, M.; Rahman, N.U.; Zia-Ul-Haq, M.; Jaffar, H.Z.E.; Manea, R. Ginseng: A dietary supplement as immune-modulator in various diseases. Trends Food Sci. Technol. 2019, 83, 12–30. [Google Scholar] [CrossRef]
- Ratan, Z.A.; Haidere, M.F.; Hong, Y.H.; Park, S.H.; Lee, J.O.; Lee, J.; Cho, J.Y. Pharmacological potential of ginseng and its major component ginsenosides. J. Ginseng Res. 2021, 45, 199–210. [Google Scholar] [CrossRef]
- Hasegawa, H. Proof of the mysterious efficacy of ginseng: Basic and clinical trials: Metabolic activation of ginsenoside: Deglycosylation by intestinal bacteria and esterification with fatty acid. J. Pharmacol. Sci. 2004, 95, 153–157. [Google Scholar] [CrossRef]
- Wan, J.Y.; Liu, P.; Wang, H.Y.; Qi, L.W.; Wang, C.Z.; Li, P.; Yuan, C.S. Biotransformation and metabolic profile of American ginseng saponins with human intestinal microflora by liquid chromatography quadrupole time-of-flight mass spectrometry. J. Chromatogr. A 2013, 1286, 83–92. [Google Scholar] [CrossRef]
- Dong, J.; Liang, W.; Wang, T.; Sui, J.; Wang, J.; Deng, Z.; Chen, D. Saponins regulate intestinal inflammation in colon cancer and IBD. Pharmacol. Res. 2019, 144, 66–72. [Google Scholar] [CrossRef]
- Im, D.S. Pro-Resolving Effect of Ginsenosides as an Anti-Inflammatory Mechanism of Panax ginseng. Biomolecules 2020, 10, 444. [Google Scholar] [CrossRef]
- Ward, S.L.; Osenkowski, P. Dog as the experimental model: Laboratory uses of dogs in the United States. Altex 2022, 39, 605–620. [Google Scholar] [CrossRef] [PubMed]
- Shearin, A.L.; Ostrander, E.A. Leading the way: Canine models of genomics and disease. Dis. Model Mech. 2010, 3, 27–34. [Google Scholar] [CrossRef]
- van Steenbeek, F.G.; Hytönen, M.K.; Leegwater, P.A.; Lohi, H. The canine era: The rise of a biomedical model. Anim. Genet. 2016, 47, 519–527. [Google Scholar] [CrossRef] [PubMed]
- Hayward, J.J.; Castelhano, M.G.; Oliveira, K.C.; Corey, E.; Balkman, C.; Baxter, T.L.; Casal, M.L.; Center, S.A.; Fang, M.; Garrison, S.J.; et al. Complex disease and phenotype mapping in the domestic dog. Nat. Commun. 2016, 7, 10460. [Google Scholar] [CrossRef]
- Lee, M.; Chang, E.B. Inflammatory Bowel Diseases (IBD) and the Microbiome-Searching the Crime Scene for Clues. Gastroenterology 2021, 160, 524–537. [Google Scholar] [CrossRef]
- Dong, L.N.; Wang, M.; Guo, J.; Wang, J.P. Role of intestinal microbiota and metabolites in inflammatory bowel disease. Chin. Med. J. 2019, 132, 1610–1614. [Google Scholar] [CrossRef]
- Nishida, A.; Inoue, R.; Inatomi, O.; Bamba, S.; Naito, Y.; Andoh, A. Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin. J. Gastroenterol. 2018, 11, 1–10. [Google Scholar] [CrossRef]
- Huang, Z.; Pan, Z.; Yang, R.; Bi, Y.; Xiong, X. The canine gastrointestinal microbiota: Early studies and research frontiers. Gut Microbes 2020, 11, 635–654. [Google Scholar] [CrossRef]
- Coelho, L.P.; Kultima, J.R.; Costea, P.I.; Fournier, C.; Pan, Y.; Czarnecki-Maulden, G.; Hayward, M.R.; Forslund, S.K.; Schmidt, T.S.B.; Descombes, P.; et al. Similarity of the dog and human gut microbiomes in gene content and response to diet. Microbiome 2018, 6, 72. [Google Scholar] [CrossRef]
- Wirtz, S.; Neufert, C.; Weigmann, B.; Neurath, M.F. Chemically induced mouse models of intestinal inflammation. Nat. Protoc. 2007, 2, 541–546. [Google Scholar] [CrossRef]
- Eichele, D.D.; Kharbanda, K.K. Dextran sodium sulfate colitis murine model: An indispensable tool for advancing our understanding of inflammatory bowel diseases pathogenesis. World J. Gastroenterol. 2017, 23, 6016–6029. [Google Scholar] [CrossRef]
- Jergens, A.E.; Crandell, J.; Morrison, J.A.; Deitz, K.; Pressel, M.; Ackermann, M.; Suchodolski, J.S.; Steiner, J.M.; Evans, R. Comparison of oral prednisone and prednisone combined with metronidazole for induction therapy of canine inflammatory bowel disease: A randomized-controlled trial. J. Vet. Intern. Med. 2010, 24, 269–277. [Google Scholar] [CrossRef]
- White, R.; Atherly, T.; Guard, B.; Rossi, G.; Wang, C.; Mosher, C.; Webb, C.; Hill, S.; Ackermann, M.; Sciabarra, P.; et al. Randomized, controlled trial evaluating the effect of multi-strain probiotic on the mucosal microbiota in canine idiopathic inflammatory bowel disease. Gut Microbes 2017, 8, 451–466. [Google Scholar] [CrossRef] [PubMed]
- Dye, T.L.; Diehl, K.J.; Wheeler, S.L.; Westfall, D.S. Randomized, controlled trial of budesonide and prednisone for the treatment of idiopathic inflammatory bowel disease in dogs. J. Vet. Intern. Med. 2013, 27, 1385–1391. [Google Scholar] [CrossRef]
- Jergens, A.E.; Simpson, K.W. Inflammatory bowel disease in veterinary medicine. Front. Biosci. (Elite Ed.) 2012, 4, 1404–1419. [Google Scholar] [CrossRef]
- Johansson, M.E.; Sjövall, H.; Hansson, G.C. The gastrointestinal mucus system in health and disease. Nat. Rev. Gastroenterol. Hepatol. 2013, 10, 352–361. [Google Scholar] [CrossRef]
- Birchenough, G.M.; Johansson, M.E.; Gustafsson, J.K.; Bergström, J.H.; Hansson, G.C. New developments in goblet cell mucus secretion and function. Mucosal. Immunol. 2015, 8, 712–719. [Google Scholar] [CrossRef] [PubMed]
- Bergstrom, K.; Shan, X.; Casero, D.; Batushansky, A.; Lagishetty, V.; Jacobs, J.P.; Hoover, C.; Kondo, Y.; Shao, B.; Gao, L.; et al. Proximal colon-derived O-glycosylated mucus encapsulates and modulates the microbiota. Science 2020, 370, 467–472. [Google Scholar] [CrossRef]
- Johansson, M.E.; Larsson, J.M.; Hansson, G.C. The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions. Proc. Natl. Acad. Sci. USA 2011, 108 (Suppl. S1), 4659–4665. [Google Scholar] [CrossRef]
- Dubbelboer, I.R.; Barmpatsalou, V.; Rodler, A.; Karlsson, E.; Nunes, S.F.; Holmberg, J.; Häggström, J.; Bergström, C.A.S. Gastrointestinal mucus in dog: Physiological characteristics, composition, and structural properties. Eur. J. Pharm. Biopharm. 2022, 173, 92–102. [Google Scholar] [CrossRef]
- Chelakkot, C.; Ghim, J.; Ryu, S.H. Mechanisms regulating intestinal barrier integrity and its pathological implications. Exp. Mol. Med. 2018, 50, 1–9. [Google Scholar] [CrossRef]
- Pope, J.L.; Bhat, A.A.; Sharma, A.; Ahmad, R.; Krishnan, M.; Washington, M.K.; Beauchamp, R.D.; Singh, A.B.; Dhawan, P. Claudin-1 regulates intestinal epithelial homeostasis through the modulation of Notch-signalling. Gut 2014, 63, 622–634. [Google Scholar] [CrossRef] [PubMed]
- Bergmann, S.; von Buenau, B.; Vidal, Y.S.S.; Haftek, M.; Wladykowski, E.; Houdek, P.; Lezius, S.; Duplan, H.; Bäsler, K.; Dähnhardt-Pfeiffer, S.; et al. Claudin-1 decrease impacts epidermal barrier function in atopic dermatitis lesions dose-dependently. Sci. Rep. 2020, 10, 2024. [Google Scholar] [CrossRef] [PubMed]
- Feldman, G.J.; Mullin, J.M.; Ryan, M.P. Occludin: Structure, function and regulation. Adv. Drug Deliv. Rev. 2005, 57, 883–917. [Google Scholar] [CrossRef] [PubMed]
- Rawat, M.; Nighot, M.; Al-Sadi, R.; Gupta, Y.; Viszwapriya, D.; Yochum, G.; Koltun, W.; Ma, T.Y. IL1B Increases Intestinal Tight Junction Permeability by Up-regulation of MIR200C-3p, Which Degrades Occludin mRNA. Gastroenterology 2020, 159, 1375–1389. [Google Scholar] [CrossRef]
- Kuo, W.T.; Zuo, L.; Odenwald, M.A.; Madha, S.; Singh, G.; Gurniak, C.B.; Abraham, C.; Turner, J.R. The Tight Junction Protein ZO-1 Is Dispensable for Barrier Function but Critical for Effective Mucosal Repair. Gastroenterology 2021, 161, 1924–1939. [Google Scholar] [CrossRef]
- Mendonsa, A.M.; Na, T.Y.; Gumbiner, B.M. E-cadherin in contact inhibition and cancer. Oncogene 2018, 37, 4769–4780. [Google Scholar] [CrossRef]
- Madsen, K.L.; Malfair, D.; Gray, D.; Doyle, J.S.; Jewell, L.D.; Fedorak, R.N. Interleukin-10 gene-deficient mice develop a primary intestinal permeability defect in response to enteric microflora. Inflamm. Bowel Dis. 1999, 5, 262–270. [Google Scholar] [CrossRef]
- Paone, P.; Cani, P.D. Mucus barrier, mucins and gut microbiota: The expected slimy partners? Gut 2020, 69, 2232–2243. [Google Scholar] [CrossRef]
- Manichanh, C.; Rigottier-Gois, L.; Bonnaud, E.; Gloux, K.; Pelletier, E.; Frangeul, L.; Nalin, R.; Jarrin, C.; Chardon, P.; Marteau, P.; et al. Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach. Gut 2006, 55, 205–211. [Google Scholar] [CrossRef]
- Matsuoka, K.; Kanai, T. The gut microbiota and inflammatory bowel disease. Semin. Immunopathol. 2015, 37, 47–55. [Google Scholar] [CrossRef]
- Guo, X.; Huang, C.; Xu, J.; Xu, H.; Liu, L.; Zhao, H.; Wang, J.; Huang, W.; Peng, W.; Chen, Y.; et al. Gut Microbiota Is a Potential Biomarker in Inflammatory Bowel Disease. Front. Nutr. 2021, 8, 818902. [Google Scholar] [CrossRef]
- Zhou, Y.; Zhi, F. Lower Level of Bacteroides in the Gut Microbiota Is Associated with Inflammatory Bowel Disease: A Meta-Analysis. Biomed. Res. Int. 2016, 2016, 5828959. [Google Scholar] [CrossRef]
- Malnick, H. Anaerobiospirillum thomasii sp. nov. an anaerobic spiral bacterium isolated from the feces of cats and dogs and from diarrheal feces of humans, and emendation of the genus Anaerobiospirillum. Int. J. Syst. Bacteriol. 1997, 47, 381–384. [Google Scholar] [CrossRef]
- Malnick, H.; Jones, A.; Vickers, J.C. Anaerobiospirillum: Cause of a “new” zoonosis? Lancet 1989, 1, 1145–1146. [Google Scholar] [CrossRef]
- Malnick, H.; Thomas, M.E.; Lotay, H.; Robbins, M. Anaerobiospirillum species isolated from humans with diarrhoea. J. Clin. Pathol. 1983, 36, 1097–1101. [Google Scholar] [CrossRef]
- Malnick, H.; Williams, K.; Phil-Ebosie, J.; Levy, A.S. Description of a medium for isolating Anaerobiospirillum spp. a possible cause of zoonotic disease, from diarrheal feces and blood of humans and use of the medium in a survey of human, canine, and feline feces. J. Clin. Microbiol. 1990, 28, 1380–1384. [Google Scholar] [CrossRef]
- Epstein, D.J.; Ernst, K.; Rogers, R.; Carmody, E.; Aguero-Rosenfeld, M. Closing the Brief Case: Anaerobiospirillum succiniciproducens Bacteremia and Pyomyositis. J. Clin. Microbiol. 2017, 55, 986–987. [Google Scholar] [CrossRef]
- De Cock, H.E.; Marks, S.L.; Stacy, B.A.; Zabka, T.S.; Burkitt, J.; Lu, G.; Steffen, D.J.; Duhamel, G.E. Ileocolitis associated with Anaerobiospirillum in cats. J. Clin. Microbiol. 2004, 42, 2752–2758. [Google Scholar] [CrossRef]
- Rudensky, B.; Wachtel, D.; Yinnon, A.M.; Raveh, D.; Schlesinger, Y. Anaerobiospirillum succiniciproducens bacteremia in a young child. Pediatr. Infect. Dis. J. 2002, 21, 575–576. [Google Scholar] [CrossRef]
- Papamichael, K.; Konstantopoulos, P.; Mantzaris, G.J. Helicobacter pylori infection and inflammatory bowel disease: Is there a link? World J. Gastroenterol. 2014, 20, 6374–6385. [Google Scholar] [CrossRef]
- Zhong, Y.; Zhang, Z.; Lin, Y.; Wu, L. The Relationship Between Helicobacter pylori and Inflammatory Bowel Disease. Arch. Iran. Med. 2021, 24, 317–325. [Google Scholar] [CrossRef] [PubMed]
- Yu, Y.; Zhu, S.; Li, P.; Min, L.; Zhang, S. Helicobacter pylori infection and inflammatory bowel disease: A crosstalk between upper and lower digestive tract. Cell Death Dis. 2018, 9, 961. [Google Scholar] [CrossRef] [PubMed]
- Tanner, S.; Katz, J.; Cominelli, F.; Regueiro, M.; Cooper, G.; Mansoor, E. Inflammatory Bowel Disease and Helicobacter pylori: Protective or Present? Inflamm. Bowel Dis. 2022, 29, 1s005–1007. [Google Scholar] [CrossRef] [PubMed]
- Kalischuk, L.D.; Inglis, G.D.; Buret, A.G. Campylobacter jejuni induces transcellular translocation of commensal bacteria via lipid rafts. Gut Pathog. 2009, 1, 2. [Google Scholar] [CrossRef] [PubMed]
- Kalischuk, L.D.; Leggett, F.; Inglis, G.D. Campylobacter jejuni induces transcytosis of commensal bacteria across the intestinal epithelium through M-like cells. Gut Pathog. 2010, 2, 14. [Google Scholar] [CrossRef] [PubMed]
- Wine, E.; Chan, V.L.; Sherman, P.M. Campylobacter jejuni mediated disruption of polarized epithelial monolayers is cell-type specific, time dependent, and correlates with bacterial invasion. Pediatr. Res. 2008, 64, 599–604. [Google Scholar] [CrossRef]
- Kalischuk, L.D.; Buret, A.G. A role for Campylobacter jejuni-induced enteritis in inflammatory bowel disease? Am. J. Physiol. Gastrointest. Liver Physiol. 2010, 298, G1–G9. [Google Scholar] [CrossRef]
- Chichlowski, M.; Hale, L.P. Bacterial-mucosal interactions in inflammatory bowel disease: An alliance gone bad. Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 295, G1139–G1149. [Google Scholar] [CrossRef]
- Xavier, R.J.; Podolsky, D.K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007, 448, 427–434. [Google Scholar] [CrossRef]
- Doulidis, P.G.; Galler, A.I.; Hausmann, B.; Berry, D.; Rodríguez-Rojas, A.; Burgener, I.A. Gut microbiome signatures of Yorkshire Terrier enteropathy during disease and remission. Sci. Rep. 2023, 13, 4337. [Google Scholar] [CrossRef] [PubMed]
- Díaz-Regañón, D.; García-Sancho, M.; Villaescusa, A.; Sainz, Á.; Agulla, B.; Reyes-Prieto, M.; Rodríguez-Bertos, A.; Rodríguez-Franco, F. Characterization of the Fecal and Mucosa-Associated Microbiota in Dogs with Chronic Inflammatory Enteropathy. Animals 2023, 13, 326. [Google Scholar] [CrossRef] [PubMed]
- Bajer, L.; Kverka, M.; Kostovcik, M.; Macinga, P.; Dvorak, J.; Stehlikova, Z.; Brezina, J.; Wohl, P.; Spicak, J.; Drastich, P. Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis. World J. Gastroenterol. 2017, 23, 4548–4558. [Google Scholar] [CrossRef]
- Jialing, L.; Yangyang, G.; Jing, Z.; Xiaoyi, T.; Ping, W.; Liwei, S.; Simin, C. Changes in serum inflammatory cytokine levels and intestinal flora in a self-healing dextran sodium sulfate-induced ulcerative colitis murine model. Life Sci. 2020, 263, 118587. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Mao, A.; Zhao, W.; Zhu, Y.; Kong, F.; Chen, D.; Si, H.; Xu, C. Gut Bacterial Community Determines the Therapeutic Effect of Ginsenoside on Canine Inflammatory Bowel Disease by Modulating the Colonic Mucosal Barrier. Microorganisms 2023, 11, 2616. https://doi.org/10.3390/microorganisms11112616
Mao A, Zhao W, Zhu Y, Kong F, Chen D, Si H, Xu C. Gut Bacterial Community Determines the Therapeutic Effect of Ginsenoside on Canine Inflammatory Bowel Disease by Modulating the Colonic Mucosal Barrier. Microorganisms. 2023; 11(11):2616. https://doi.org/10.3390/microorganisms11112616
Chicago/Turabian StyleMao, Aipeng, Weigang Zhao, Yuhang Zhu, Fantao Kong, Danyang Chen, Huazhe Si, and Chao Xu. 2023. "Gut Bacterial Community Determines the Therapeutic Effect of Ginsenoside on Canine Inflammatory Bowel Disease by Modulating the Colonic Mucosal Barrier" Microorganisms 11, no. 11: 2616. https://doi.org/10.3390/microorganisms11112616